172 related articles for article (PubMed ID: 35731998)
1. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
Almassi N; Whiting K; Toubaji A; Lenis AT; Jordan EJ; Won H; Regazzi AM; Chen YB; Gopalan A; Sirintrapun SJ; Fine SW; Tickoo SK; Ostrovnaya I; Pietzak EJ; Cha EK; Goh AC; Donahue TF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Teo MY; Funt SA; Rosenberg JE; Reuter VE; Bajorin DF; Solit DB; Al-Ahmadie H; Iyer G
JCO Precis Oncol; 2022 Jun; 6():e2100392. PubMed ID: 35731998
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
Almassi N; Vertosick EA; Sjoberg DD; Wong NC; Huang C; Pietzak EJ; Cha EK; Donahue TF; Dalbagni G; Bochner BH; Iyer G; Rosenberg JE; Bajorin DF; Al-Ahmadie H; Goh AC
BJU Int; 2022 Apr; 129(4):463-469. PubMed ID: 33866683
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
6. Comparative genomic profiling of glandular bladder tumours.
Maurer A; Ortiz-Bruechle N; Guricova K; Rose M; Morsch R; Garczyk S; Stöhr R; Bertz S; Golz R; Reis H; Bremmer F; Zimpfer A; Siegert S; Kristiansen G; Schwamborn K; Gassler N; Knuechel R; Gaisa NT;
Virchows Arch; 2020 Sep; 477(3):445-454. PubMed ID: 32198650
[TBL] [Abstract][Full Text] [Related]
7. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O
Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749
[TBL] [Abstract][Full Text] [Related]
8. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
Bollito ER; Pacchioni D; Lopez-Beltran A; Volante M; Terrone C; Casetta G; Mari M; DePompa R; Cappia S; Papotti M
Anal Quant Cytol Histol; 2005 Aug; 27(4):218-24. PubMed ID: 16220833
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers.
Rao Q; Williamson SR; Lopez-Beltran A; Montironi R; Huang W; Eble JN; Grignon DJ; Koch MO; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Cheng L
Mod Pathol; 2013 May; 26(5):725-32. PubMed ID: 23348900
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.
Roy S; Pradhan D; Ernst WL; Mercurio S; Najjar Y; Parikh R; Parwani AV; Pai RK; Dhir R; Nikiforova MN
Mod Pathol; 2017 Aug; 30(8):1133-1143. PubMed ID: 28548125
[TBL] [Abstract][Full Text] [Related]
12. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
15. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
17. A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma.
Nagumo Y; Kojima T; Shiga M; Kandori S; Kimura T; Takaoka EI; Onozawa M; Miyazaki J; Kawai K; Ishikawa H; Sakurai H; Nishiyama H
Int J Clin Oncol; 2020 Feb; 25(2):354-361. PubMed ID: 31595343
[TBL] [Abstract][Full Text] [Related]
18. Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma.
Lee YJ; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2014; 9(9):e107027. PubMed ID: 25191845
[TBL] [Abstract][Full Text] [Related]
19. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.
Tripathi N; Jo Y; Tripathi A; Sayegh N; Li H; Nussenzveig R; Haaland B; Thomas VM; Gupta S; Maughan BL; Swami U; Pal SK; Grivas P; Agarwal N; Sirohi D
Urol Oncol; 2022 Nov; 40(11):493.e1-493.e7. PubMed ID: 35918248
[TBL] [Abstract][Full Text] [Related]
20. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
Teo MY; Guercio BJ; Arora A; Hao X; Regazzi AM; Donahue T; Herr HW; Goh AC; Cha EK; Pietzak E; Donat SM; Dalbagni G; Bochner BH; Olgac S; Sarungbam J; Sirintrapun SJ; Chen YB; Gopalan A; Fine SW; Tickoo SK; Reuter VE; Weigelt B; Schultheis AM; Funt SA; Bajorin DF; Solit DB; Iyer G; Ostrovnaya I; Rosenberg JE; Al-Ahmadie H
Clin Genitourin Cancer; 2022 Oct; 20(5):431-441. PubMed ID: 35676169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
